There's good news and bad news if you own shares of Alnylam Pharmaceuticals ( ALNY -3. The good news is that the biotech stock is up around 25% since the end of July.
Read the original report for the complete account of this story.
POLARIS INSIGHTS
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right
